Format

Send to

Choose Destination
Ophthalmologe. 2012 May;109(5):474-8. doi: 10.1007/s00347-012-2554-7.

[Access to healthcare services for elderly patients with neovascular age-related macular degeneration].

[Article in German]

Author information

1
Universitätsaugenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland.

Abstract

BACKGROUND:

Neovascular (nv) age-related macular degeneration (AMD) is the leading cause of blindness in Germany and is usually treated with monthly injections of anti-VEGF agents. The current level and the estimated need of service provision for nv-AMD were assessed.

METHODS:

Current levels of service provision with ranibizumab (Lucentis) were documented in 3,633 patients in the WAVE study, the currently largest observational study in Germany on the use of anti-VEGF agents. The expected need was calculated using German population figures for 2010 and available prevalence data. Both were stratified by age and gender and descriptively analyzed.

RESULTS:

A larger number of younger patients with nv-AMD (<‚ÄČ75 years) than expected were treated in the WAVE study. Expected need in the age groups 75-84 years and 84 years and older was much higher than the proportion of patients actually treated in these age groups (up to 3 times). Based on expected need, women accessed treatment less often than men.

CONCLUSION:

In the WAVE study, less elderly persons and in particular elderly women seemed to access treatment for nv-AMD than expected. Future studies should investigate barriers in accessing treatment for nv-AMD and how to address these problems.

PMID:
22581049
DOI:
10.1007/s00347-012-2554-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center